Refractory or relapsed symptomatic multiple myeloma
Conditions
Interventions
Patients were administrated with lenalidomide of 5 mg per day for 21 days and dexamethasone of 8 mg per day weekly for a cycle of 28 days. Numbers of cycle are not determined.
Sponsors
Nishiwaki municipal hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: *Refractory or relapsed symptomatic multiple myeloma *patient must be 70 or more than 70 years old at registration, or patients age of lower than 70 are also included if they are considered to be intolerable for ordinary treatment of lenalidomide because of the comorbidities such as previously infectious disease. *Patient must be informed consent with their signature.
Exclusion criteria
Exclusion criteria: *Patients who have allergy for the drugs used in this study *Patients who have active infectious disease *Patients who are decided as inappropriate by corresponding doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Partial remission rate within a year after the therapy | — |
Countries
Japan
Contacts
Public ContactChiho Kinugasa
Nishiwaki municipal hospital management division
Outcome results
None listed